NASDAQ · LTRN
Healthcare · Biotechnology
$0.91
Down-$0.04 (-4.58%)
Updated Oct 8, 2026, 5:44 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LTRN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
LTRN closed at $0.91 after 21 trading sessions, down 48.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $0.9538 | $0.9999 | $0.89 | $0.91 | 224.08K |
| Oct 6, 2026 | $0.96 | $1.07 | $0.92 | $0.9537 | 388.66K |
| Oct 5, 2026 | $0.88 | $0.97 | $0.86 | $0.9401 | 276.17K |
| Oct 2, 2026 | $1.03 | $1.04 | $0.8375 | $0.8601 | 433.63K |
| Oct 1, 2026 | $1.00 | $1.05 | $0.9817 | $1.00 | 253.57K |
| Sep 30, 2026 | $1.10 | $1.16 | $0.97 | $1.01 | 420.7K |
| Sep 29, 2026 | $1.11 | $1.1199 | $1.0102 | $1.085 | 363.73K |
| Sep 28, 2026 | $1.25 | $1.2705 | $1.08 | $1.09 | 461.47K |
| Sep 25, 2026 | $1.19 | $1.28 | $1.16 | $1.22 | 220.43K |
| Sep 24, 2026 | $1.36 | $1.36 | $1.165 | $1.21 | 515.48K |
| Sep 23, 2026 | $1.35 | $1.54 | $1.3401 | $1.39 | 292.34K |
| Sep 22, 2026 | $1.45 | $1.64 | $1.35 | $1.36 | 749.47K |
| Sep 21, 2026 | $1.59 | $1.625 | $1.47 | $1.50 | 248.51K |
| Sep 18, 2026 | $1.75 | $1.75 | $1.55 | $1.55 | 190.53K |
| Sep 17, 2026 | $1.93 | $1.9502 | $1.71 | $1.71 | 278.68K |
| Sep 16, 2026 | $1.73 | $1.96 | $1.73 | $1.93 | 362.63K |
| Sep 15, 2026 | $1.71 | $1.73 | $1.67 | $1.70 | 128.17K |
| Sep 14, 2026 | $1.74 | $1.79 | $1.71 | $1.71 | 114.41K |
| Sep 11, 2026 | $1.775 | $1.82 | $1.70 | $1.71 | 109.81K |
| Sep 10, 2026 | $1.73 | $1.8694 | $1.72 | $1.76 | 163.03K |
| Sep 9, 2026 | $1.82 | $1.86 | $1.76 | $1.77 | 181.07K |
The latest Smart Investors Daily articles mentioning LTRN.
Company
Market Activity
Research & News
LTRN research
Company profile and research snapshot.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2025 | Lake Street | Buy | — |
| Apr 25, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 10, 2023 | EF Hutton | Buy | — |
| Jun 26, 2023 | EF Hutton | Buy | — |
| May 18, 2023 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Jul 23, 2026
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins
businesswire.com · Dec 3, 2025
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LTRN.
